Results 41 to 50 of about 8,117 (271)
Efficacy and safety of treatment with benralizumab for eosinophilic asthma
International Immunopharmacology, 2022 Eosinophilic asthma accounts for 40% to 50% of asthmatic patients. However, 5% to 10% of patients with asthma need high-dose drug control, which is clinically referred to as severe asthma patients. Interleukin (IL)-5 plays an important role in the proliferation, maturation, and migration of eosinophils.
Miaojuan Zhu, Jiong Yang, Yifei Chen
openalex +3 more sources
Eosinophilic bronchiolitis successfully treated with benralizumab [PDF]
BMJ Case Reports, 2021 A 53-year-old non-smoking Japanese woman was admitted to our hospital with a 20-year history of wet cough and dyspnoea on exertion. Bronchial asthma (BA) had been diagnosed 20 years earlier. Although she has been treated with high-dose inhaled corticosteroid, she had experienced frequent exacerbation of BA, and short-term oral corticosteroid bursts ...
Keishi Sugino +3 more
openaire +3 more sources
Фармакоэкономика, 2022 Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe ...
M. V. Zhuravleva +3 more
doaj +1 more source
Biomolecules, 2023 Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu +17 more
doaj +1 more source
Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia:Case report [PDF]
, 2021 A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection.
Bethlehem, Carina +4 more
core +1 more source
Respiratory Research, 2023 Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain.
A. Padilla-Galo +21 more
semanticscholar +1 more source
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
, 2020 BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source
Allergy, Asthma & Clinical Immunology, 2021 Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian +3 more
doaj +1 more source
BMC Pulmonary Medicine, 2020 Background Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA).
Takanori Numata +10 more
doaj +1 more source
Eosinophilic cystitis refractory to steroids successfully treated with benralizumab: A case report
Frontiers in Allergy, 2023 We report a case of a 66-year-old male diagnosed with refractory to oral corticosteroids eosinophilic cystitis (EoC). Hematuria was the first and only sign of the disease that was otherwise asymptomatic, and the only abnormal lab finding he had was ...
George N. Konstantinou +1 more
doaj +1 more source